PMID- 16919544
OWN - NLM
STAT- MEDLINE
DCOM- 20061013
LR  - 20151119
IS  - 0026-0495 (Print)
IS  - 0026-0495 (Linking)
VI  - 55
IP  - 9
DP  - 2006 Sep
TI  - Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion 
      molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance 
      and glucose intolerance--the Chennai Urban Rural Epidemiology Study (CURES).
PG  - 1232-8
AB  - The aim of this cross-sectional study was to assess the association of insulin 
      resistance (IR) with inflammatory molecules C-reactive protein (CRP), interleukin 
      6 (IL-6), vascular cell adhesion molecule 1 (VCAM-1), and monocyte chemotactic 
      protein 1 (MCP-1) in urban South Indian subjects. The following groups were 
      selected from the population-based Chennai Urban Rural Epidemiology Study: group 
      1 composed of 50 healthy subjects with normal glucose tolerance without IR; group 
      2 consisted of 50 normal glucose-tolerant subjects with IR as defined by 
      homeostasis model assessment of IR (HOMA-IR); group 3 consisted of 50 subjects 
      with impaired glucose tolerance (IGT); and groups 4 and 5 each comprised 50 newly 
      diagnosed and known type 2 diabetic subjects, respectively. The inclusion 
      criteria included nonsmokers; normal resting 12-lead electrocardiogram; and 
      absence of angina, myocardial infarction, or history of any known vascular, 
      infectious, or inflammatory diseases, and not on statins or aspirin. Normal 
      glucose tolerance without IR had the lowest values of CRP, IL-6, and VCAM-1 (CRP, 
      1.32 mg/L; IL-6, 12.56 pg/mL; VCAM-1, 277 pg/mL) followed by normal glucose 
      tolerance with IR (CRP, 2.25 mg/L; IL-6, 20.97 pg/mL; VCAM-1, 289 pg/mL), 
      impaired glucose tolerance (CRP, 2.37 mg/L; IL-6, 22.11 pg/mL; VCAM-1, 335 
      pg/mL), newly diagnosed diabetic subjects (CRP, 3.24 mg/L; IL-6, 23.21 pg/mL; 
      VCAM-1, 568 pg/mL), and the highest levels were in the known diabetic subjects 
      (CRP, 4.08 mg/L; IL-6, 29.44 pg/mL; VCAM-1, 577 pg/mL). This trend was 
      statistically significant (P < .001). However, monocyte chemotactic protein 1 did 
      not show such a trend and did not differ significantly between groups. In 
      nondiabetic subjects, Pearson correlation analysis revealed that CRP (r = 0.299; 
      P < .001) and IL-6 (r = 0.180, P = .025) had a significant correlation with 
      HOMA-IR. Monocyte chemotactic protein 1 did not show any correlation with 
      HOMA-IR. Multiple linear regression analysis revealed CRP to be significantly 
      associated with HOMA-IR (beta = .229; P < .001) and this was unaltered by the 
      addition of waist and IL-6 into the model (beta = .158; P = .028). In conclusion, 
      this study shows that in Asian Indians, inflammatory markers (CRP, IL-6, and 
      VCAM-1) increase with increasing degrees of glucose intolerance.
FAU - Deepa, Raj
AU  - Deepa R
AD  - Madras Diabetes Research Foundation and Dr. Mohan's Diabetes Specialities Centre, 
      Gopalapuram, Chennai 600 086, India.
FAU - Velmurugan, Kaliyaperumal
AU  - Velmurugan K
FAU - Arvind, Kannan
AU  - Arvind K
FAU - Sivaram, Pillarisetti
AU  - Sivaram P
FAU - Sientay, Cahoon
AU  - Sientay C
FAU - Uday, Saxena
AU  - Uday S
FAU - Mohan, Viswanathan
AU  - Mohan V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-6)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - C-Reactive Protein/*analysis
MH  - Chemokine CCL2/*blood
MH  - Cross-Sectional Studies
MH  - Female
MH  - Glucose Intolerance/*blood/epidemiology
MH  - Humans
MH  - India/epidemiology
MH  - Inflammation/blood
MH  - *Insulin Resistance
MH  - Interleukin-6/*blood
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Vascular Cell Adhesion Molecule-1/*blood
EDAT- 2006/08/22 09:00
MHDA- 2006/10/14 09:00
CRDT- 2006/08/22 09:00
PHST- 2006/01/31 00:00 [received]
PHST- 2006/05/14 00:00 [accepted]
PHST- 2006/08/22 09:00 [pubmed]
PHST- 2006/10/14 09:00 [medline]
PHST- 2006/08/22 09:00 [entrez]
AID - S0026-0495(06)00175-2 [pii]
AID - 10.1016/j.metabol.2006.05.008 [doi]
PST - ppublish
SO  - Metabolism. 2006 Sep;55(9):1232-8. doi: 10.1016/j.metabol.2006.05.008.